CN Patent

CN121532218A — 前列腺特异性膜抗原（psma）放射性标记抑制剂[18f]dcfpyl的改进的合成

Assigned to Progenics Pharmaceuticals Inc · Expires 2026-02-13 · 0y expired

What this patent protects

本文中提供了方法和相关组合物，包括试剂盒，其用于改进[ 18 F]DCFPyL的合成、制备和/或储存。还提供了使用[ 18 F]DCFPyL的方法，例如用于成像。

USPTO Abstract

本文中提供了方法和相关组合物，包括试剂盒，其用于改进[ 18 F]DCFPyL的合成、制备和/或储存。还提供了使用[ 18 F]DCFPyL的方法，例如用于成像。

Drugs covered by this patent

Patent Metadata

Patent number: CN121532218A
Jurisdiction: CN
Classification: —
Expires: 2026-02-13
Drug substance claim: No
Drug product claim: No
Assignee: Progenics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.